<DOC>
	<DOCNO>NCT01532843</DOCNO>
	<brief_summary>Treatment nucleoside analogue subsequent viral decline show partially restore immune hyporesponsiveness chronic hepatitis B patient . Recent pilot study investigate whether effect lower viral load nucleoside analogue therapy prior initiation peginterferon result higher sustained off-treatment response show contradictory finding . The aim study investigate sustain off-treatment response peginterferon alfa-2b chronic HBeAg-positive hepatitis B patient pretreated nucleos ( ) ide analogue , thereby lower viral load</brief_summary>
	<brief_title>Lowering Viral Load With Nucleos ( T ) Ide Analogues Prior Peginterferon Alfa-2b Treatment Increase Sustained Response HBeAg-positive Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Chronic hepatitis B ( HBsAg positive &gt; 6 month ) HBeAg positive , antiHBe negative within 4 week prior initiation peginterferon alfa2b HBV DNA &lt; 2000 IU/ml within one month prior initiation peginterferon alfa2b minimum 12 month treatment either Entecavir ( one 3 brand ) Tenofovir ALT &lt; 5x ULN Compensated liver disease Age ≥ 18 year ≤ 70 year Written inform consent Treatment investigational drug within 30 day entry protocol Treatment Telbivudine Severe hepatitis activity document ALT &gt; 5 x ULN History decompensated cirrhosis ( defined jaundice presence cirrhosis , ascites , bleed gastric esophageal varix encephalopathy ) Preexistent neutropenia ( neutrophils &lt; 1,500/mm3 ) thrombocytopenia ( platelet &lt; 90,000/mm3 ) Coinfection hepatitis C virus human immunodeficiency virus ( HIV ) Other acquire inherited cause liver disease : alcoholic liver disease , obesity induce liver disease , drug relate liver disease , autoimmune hepatitis , hemochromatosis , Wilson 's disease alpha1 antitrypsin deficiency Alpha fetoprotein &gt; 50 ng/ml Hyper hypothyroidism ( subject require medication maintain TSH level normal range eligible inclusion/exclusion criterion meet ) Immune suppressive treatment within previous 6 month Contraindications alfainterferon therapy like suspect hypersensitivity interferon Peginterferon know preexist medical condition could interfere patient 's participation completion study . Pregnancy , breastfeed Other significant medical illness might interfere study : significant pulmonary dysfunction previous 6 month , malignancy skin basocellular carcinoma previous 5 year , immunodeficiency syndrome ( e.g . HIV positivity , autoimmune disease , organ transplant cornea hair transplant ) Any medical condition requiring , likely require chronic systemic administration steroid , course study Substance abuse , alcohol ( &gt; 80 g/day ) , I.V . drug inhale drug past 2 year . Any condition opinion investigator would make patient unsuitable enrollment , could interfere patient participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>sustain response</keyword>
	<keyword>peginterferon</keyword>
	<keyword>nucleos ( ) ide analogue</keyword>
</DOC>